The phase I/II SYMPHONY trial (BLU-945-1101; NCT04862780) is currently ongoing to evaluate the antitumor activity, tolerability, and safety of this compound as a monotherapy and in combination with osimertinib in patients with EGFR-mutated NSCLC [199]. Here, EGFR is linked to non-small cell lung carcinoma.